ZP4207(Dasiglucagon) Administered to T1D Patients to Assess the PK and PD Compared to Marketed Glucagon
Completed
Zealand Pharma
Phase 2
2016-12-01
The trial is a single-centre, randomised, sequential, cross-over trial assessing
pharmacokinetic and pharmacodynamic responses after micro-doses of ZP4207 (dasiglucagon*)
administered subcutaneously to patients with type 1 diabetes mellitus under euglycaemic and
hypoglycaemic conditions and compared to marketed glucagon.
*dasiglucagon is the proposed International Nonproprietary Name (pINN) for ZP4207
Feasibility Trial Testing the Bionic Pancreas With ZP4207
Completed
Beta Bionics, Inc.
Phase 2
2016-11-01
The purpose of this study was to determine whether the Bionic Pancreas with ZP4207
(dasiglucagon*) was feasible to improve glycemic control in adults with type 1 diabetes
mellitus.
*dasiglucagon is the proposed International Nonproprietary Name (pINN) for ZP4207
Feasibility Trial Testing the Bionic Pancreas With ZP4207
Completed
Massachusetts General Hospital
Phase 2
2016-11-01
The purpose of this study was to determine whether the Bionic Pancreas with ZP4207
(dasiglucagon*) was feasible to improve glycemic control in adults with type 1 diabetes
mellitus.
*dasiglucagon is the proposed International Nonproprietary Name (pINN) for ZP4207
Feasibility Trial Testing the Bionic Pancreas With ZP4207
Completed
Zealand Pharma
Phase 2
2016-11-01
The purpose of this study was to determine whether the Bionic Pancreas with ZP4207
(dasiglucagon*) was feasible to improve glycemic control in adults with type 1 diabetes
mellitus.
*dasiglucagon is the proposed International Nonproprietary Name (pINN) for ZP4207
A Trial to Evaluate the Immunogenicity of Dasiglucagon and GlucaGen in Patients With Type 1 Diabetes Mellitus
Completed
SynteractHCR
Phase 3
2017-06-28
The trial's objective is to evaluate the immunogenicity of repeated single doses of
dasiglucagon* and GlucaGen following subcutaneous (SC) administration in patients with type 1
diabetes mellitus (T1DM) and further to evaluate the safety and tolerability of dasiglucagon
and GlucaGen.
*dasiglucagon is the proposed International Nonproprietary Name (pINN) for ZP4207
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
